Fig 1: Collagen IV abundance is increased and associated with poor outcomes in chemotherapy-treated human patients with TNBC. A, Immunostaining of human TNBC sections retrieved from diagnostic biopsy (pre–AC-T) and surgical resections (post–AC-T) stained for collagen IV and nuclei. H&E staining for histologic comparison. Scale bar, 100 µm. B, Collagen IV signal intensity measured from matched pre– and post–AC-T sections. C, mRNA expression data from patients with TNBC with or without chemotherapy (METABRIC) showing expression of collagen IV α chains. D–F, Kaplan-Meier curves of all patients with TNBC (D), chemotherapy-treated patients with TNBC (E), or systemically untreated patients with TNBC (F) visualizing patient outcomes based on average expression of five collagen IV α chains (COL4A1-5). Data show mean ± SD [n = 7 paired biopsies and surgical resections (A and B) or 517 untreated vs. 213 chemotherapy-treated patients with TNBC (C–H)]. For gene expression, significance was determined by unpaired t test. For survival curves, patients were stratified by median COL4A1-5 expression and significance was determined by log-rank test. ***, P < 0.005. a.u., arbitrary units, Col IV, collagen IV; chemo, chemotherapy.
Fig 2: Human RNA-Seq data from human white adipose tissue.Scaled mean expression (blue low red high) and percentage of cells (size of the dot) of human white adipose tissue expressing (A) COL4A1–6 and (B) COL6A1–6 (excluding COL6A4 not expressed in humans). (C) COL4A1–3 and COL6A1–3 expression by female human subcutaneous adipocytes. (D) COL4A1–3 and COL6A1–3 expression by female human subcutaneous ASPC. Data from the Broad Institute [48].
Supplier Page from Abcam for Native Human Collagen IV protein